Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency

If approved, this tablet would be the first protease inhibitor-based STR option indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents. This new treatment would combine the protease inhibitor, darunavir (DRV, D, 800 mg), with the pharmacokinetic enhancer, cobicistat (COBI, C, 150 mg) and the nucleoside reverse transcriptase inhibitors emtricitabine (FTC, F, 200 mg) and tenofovir alafenamide (TAF 10 mg), in one single tablet.

Published
13 September 2016
From
Janssen-Cilag press release
Glaxo Bets It Can Shake Up HIV Treatment

GlaxoSmithKline PLC is pinning the future of its HIV business on an audacious bet. They hope their latest HIV pill is powerful enough to suppress the virus with the help of just one other drug.

Published
30 August 2016
From
Wall Street Journal
German medicines watchdog rejects ‘new tenofovir’ pill

The German health technology assessment agency IQWiG has announced that it finds no advantage in Descovy, a combination pill containing a new version of the HIV

Published
22 August 2016
By
Gus Cairns
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude.

Published
19 August 2016
From
German Institute for Quality and Efficiency in Health Care
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

Published
18 August 2016
From
STAT
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Published
16 August 2016
From
ViiV press release
Once-daily raltegravir works as well as twice-daily for initial HIV treatment

A new formulation of the integrase inhibitor raltegravir (Isentress) taken once daily suppressed HIV viral load as well as the older formulation taken twice a day in people

Published
26 July 2016
By
Liz Highleyman
Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment

A two-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a

Published
25 July 2016
By
Liz Highleyman
Long-acting injectable drugs work well for HIV maintenance therapy

Two long-acting injectable antiretrovirals – cabotegravir and rilpivirine – administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load,

Published
22 July 2016
By
Liz Highleyman
← First12345...92Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close